# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k171103   
B. Purpose for Submission: New device   
C. Measurand: Thyroid-stimulating hormone (TSH)   
D. Type of Test: Chemiluminescent Enzyme Immunoassay   
E. Applicant: Fujirebio Diagnostics, Inc.   
F. Proprietary and Established Names: Lumipulse G TSH-III Immunoreaction Cart

G. Regulatory Information:

<table><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>JLW</td><td rowspan=1 colspan=1>II</td><td rowspan=1 colspan=1>21 CFR 862.1690, Thyroidstimulating hormone test system</td><td rowspan=1 colspan=1>Chemistry(75)</td></tr></table>

# H. Intended Use:

1. Intended use(s): See indications for use

2. Indication(s) for use:

# Lumipulse G TSH-III Immunoreaction Cartridges

For in vitro diagnostic use.

Lumipulse G TSH-III is a Chemiluminescent Enzyme Immunoassay (CLEIA) for the quantitative determination of thyroid stimulating hormone (TSH) in human serum on the LUMIPULSE G System. Lumipulse G TSH-III is to be used as an aid in the diagnosis of thyroid or pituitary disorders.

3. Special conditions for use statement(s): For prescription use.

4. Special instrument requirements: LUMIPULSE G1200 System

# I. Device Description:

The Lumipulse G TSH-III Immunoreaction Cartridges consist of the following:

1) Antibody-coated particle solution containing $2 0 0 ~ \mu \mathrm { g / m L }$ mouse anti-human monoclonal antibody-coated particles, protein stabilizers (bovine and mouse) and chemical stabilizers in $0 . 1 5 { \mathrm { M } }$ sodium chloride/Tris buffer.   
2) Enzyme-labeled antibody solution containing $0 . 3 ~ \mu \mathrm { g / m L }$ alkaline phosphatase-labeled mouse anti-TSH monoclonal antibody, protein stabilizers (bovine and mouse), and chemical stabilizers in $0 . 1 5 { \mathrm { M } }$ sodium chloride/MES buffer.

# J. Substantial Equivalence Information:

1. Predicate device name(s): Abbott ARCHITECT TSH 2. Predicate 510(k) number(s): k983442

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities and Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Candidate Device:Lumipulse G TSH-IIIk171103</td><td rowspan=1 colspan=1>Predicate Device:Abbott ARCHITECT TSHk983442</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Assay for the quantitativedetermination of TSH</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay Range</td><td rowspan=1 colspan=1>0.02 - 100 μIU/mL</td><td rowspan=1 colspan=1>0.00 - 100 μIU/mL</td></tr><tr><td rowspan=1 colspan=1>Assay Type</td><td rowspan=1 colspan=1>Two-step sandwichimmunoassay based onchemiluminescenttechnology</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Principle of Operation</td><td rowspan=1 colspan=1>Automated QuantitativeChemiluminescent EnzymeImmunoassay</td><td rowspan=1 colspan=1>ChemiluminescentMicroparticleImmunoassay</td></tr><tr><td rowspan=1 colspan=1>Specimen Type</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Serum or plasma</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI EP05-A3: Evaluation of Precision of Quantitative Measurement Methods, $3 ^ { \mathrm { r d } }$ Edition

CLSI EP06-A: Evaluation of the Linearity of Quantitative Measurement Procedures; A Statistical Approach, $2 ^ { \mathrm { n d } }$ Edition

CLSI EP07-A2: Interference Testing in Clinical Chemistry, $2 ^ { \mathrm { n d } }$ Edition

CLSI EP09-A3: Measurement Procedure Comparison and Bias Estimation Using Patient Samples, $3 ^ { \mathrm { r d } }$ Edition

CLSI EP17-A2: Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures, $2 ^ { \mathrm { n d } }$ Edition

CLSI EP25-A: Evaluation of Stability of In Vitro Diagnostic Reagents, Approved Guideline

CLSI EP28-A3c: Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory, $3 ^ { \mathrm { r d } }$ Edition

# L. Test Principle:

Lumipulse G TSH-III is an assay system for the quantitative measurement of TSH in serum specimens based on CLEIA technology by a two-step sandwich immunoassay method on the LUMIPULSE G1200 System. TSH in specimens specifically binds to mouse anti-human TSH monoclonal antibody on the particles, and antigen-antibody immunocomplexes are formed. The particles are washed and rinsed to remove unbound materials.

Alkaline phosphatase-labeled mouse anti-human TSH monoclonal antibody specifically binds to TSH of the immunocomplexes on the particles, and additional immunocomplexes are formed. The particles are washed and rinsed to remove unbound materials. Substrate solution is added and mixed with the particles. AMPPD (3-(2'-spiroadamantane)-4-methoxy4-(3"-phosphoryloxy) phenyl-1, 2-dioxetane disodium salt) contained in the substrate solution is dephosphorylated by the catalysis of alkaline phosphatase indirectly conjugated to particles. Luminescence (at a maximum wavelength of $4 7 7 \mathrm { n m }$ ) is generated by the cleavage reaction of dephosphorylated AMPPD. The luminescent signal is proportional to the amount of TSH.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Five panels (4 native serum pools and one spiked serum pool) were each assayed over 20 days, in duplicate, two runs per day, for a total of 80 results per sample. A multisite precision study was also conducted using four serum panels at three additional sites, where the panels were run in triplicate, twice per day, for five days. Lot-to-lot precision studies for three paired reagent and calibrators lots were also performed at one site using four serum panels tested in triplicate, two runs per day, for five days. All lots of reagents and the multi-site precision study yielded similar results.

The results of the 20-day precision study are shown in the table below $\mathrm { \Delta } \mathrm { n } = 8 0$ for each panel):

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>Mean(μIU/mL)</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Between Run</td><td rowspan=1 colspan=2>Between Day</td><td rowspan=1 colspan=2>WithinLaboratory(Total)</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Panel 1</td><td rowspan=1 colspan=1>0.365</td><td rowspan=1 colspan=1>0.012</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.001</td><td rowspan=1 colspan=1>0.2%</td><td rowspan=1 colspan=1>0.012</td><td rowspan=1 colspan=1>3.3%</td></tr><tr><td rowspan=1 colspan=1>Panel 2</td><td rowspan=1 colspan=1>1.029</td><td rowspan=1 colspan=1>0.018</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>0.044</td><td rowspan=1 colspan=1>4.3%</td><td rowspan=1 colspan=1>0.042</td><td rowspan=1 colspan=1>4.1%</td><td rowspan=1 colspan=1>0.063</td><td rowspan=1 colspan=1>6.2%</td></tr><tr><td rowspan=1 colspan=1>Panel 3</td><td rowspan=1 colspan=1>4.533</td><td rowspan=1 colspan=1>0.086</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>0.018</td><td rowspan=1 colspan=1>0.4%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.088</td><td rowspan=1 colspan=1>1.9%</td></tr><tr><td rowspan=1 colspan=1>Panel 4</td><td rowspan=1 colspan=1>8.773</td><td rowspan=1 colspan=1>0.098</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>0.261</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>0.427</td><td rowspan=1 colspan=1>4.9%</td><td rowspan=1 colspan=1>0.510</td><td rowspan=1 colspan=1>5.8%</td></tr><tr><td rowspan=1 colspan=1>Panel 5</td><td rowspan=1 colspan=1>73.991</td><td rowspan=1 colspan=1>1.585</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>2.125</td><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=1>3.950</td><td rowspan=1 colspan=1>5.3%</td><td rowspan=1 colspan=1>4.757</td><td rowspan=1 colspan=1>6.4%</td></tr></table>

# b. Linearity/assay reportable range:

Linearity

A high TSH serum pool was created using native samples with known high TSH values. The high TSH serum pool was serially diluted with a low sample TSH pool that was created by ultrafiltration of charcoal adsorbed human serum to create 14 TSH serum pools. All 14 TSH serum pools were assayed four times.

The results are summarized in the table below:

<table><tr><td rowspan=1 colspan=1>Samplenumber</td><td rowspan=1 colspan=1>Expected concentration(μIU/mL)</td><td rowspan=1 colspan=1>Mean concentration(μIU/mL)</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>220.00</td><td rowspan=1 colspan=1>227.804</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>127.571</td><td rowspan=1 colspan=1>135.220</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>71.531</td><td rowspan=1 colspan=1>75.283</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>27.565</td><td rowspan=1 colspan=1>27.828</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>10.708</td><td rowspan=1 colspan=1>10.450</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>4.101</td><td rowspan=1 colspan=1>3.834</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>1.254</td><td rowspan=1 colspan=1>1.210</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0.400</td><td rowspan=1 colspan=1>0.394</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0.160</td><td rowspan=1 colspan=1>0.159</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0.058</td><td rowspan=1 colspan=1>0.059</td></tr><tr><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>0.024</td><td rowspan=1 colspan=1>0.021</td></tr><tr><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0.012</td><td rowspan=1 colspan=1>0.012</td></tr><tr><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>0.007</td><td rowspan=1 colspan=1>0.006</td></tr><tr><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>0.001</td><td rowspan=1 colspan=1>0.001</td></tr></table>

The linear regression equation obtained was:

$$
\mathbf { y } = 1 . 0 3 ( \mathbf { x } ) + 0 . 0 0 1 ; \mathbf { R } ^ { 2 } = 0 . 9 9 6 2
$$

The linearity study supports the claimed measuring range of 0.02 to $1 0 0 ~ \mathrm { \mu I U / m L }$ .

# Dilution Recovery

Verification studies were performed to determine the sample recovery after a 1:10 dilution is performed either manually or automatically by the LUMIPULSE G1200 system. Several serum samples were spiked with TSH WHO International Standard to target values up to $9 0 0 \mu \mathrm { I U / m L }$ . Each sample was diluted 1:10 manually and onboard the LUMIPULSE G1200 system with the Lumipulse G Specimen Diluent 1. All samples were run in triplicate. The average percent differences for the diluted sample versus the expected concentration was within $10 \%$ . The dilution study results support the sponsor’s labeling claims that samples with TSH concentrations above the 100 $\mu \mathrm { I U / m L }$ may be diluted 1:10 either manually or on-onboard the analyzer to obtain results up to $1 0 0 0 ~ \mathrm { \mu I U / m L }$ .

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

# Traceability:

The Lumipulse G TSH-III calibrators are prepared gravimetrically and are traceable to in-house reference calibrators, whose values have been assigned to the $3 ^ { \mathrm { r d } }$ International Standard, 2003 (code: 81/565) provided by the National Institute for Biological Standards and Control.

# Reagent Stability:

The shelf life for the Lumipulse G TSH-III Immunoreaction Cartridges is 12 months at $2 - 1 0 \ ^ { \circ } \mathrm { C } _ { \mathrm { \ i } }$ , and can be stored on-board the LUMIPULSE G1200 System for a maximum of 30 days. The shelf-life stability protocols and acceptance criteria were reviewed and found to be acceptable.

# d. Detection limit:

# Limit of Blank:

Two panels of zero analyte serum were created by ultrafiltration of charcoal adsorbed human serum. The panels were tested in duplicate using two LUMIPULSE G1200 Instruments and two reagent lots over 15 testing days ( $\mathrm { \Delta } \ln = 6 0$ for each panel and lot combination). The limit of blank was estimated by the 95th percentile of 60 values for each lot. The limit of blank was determined to be $0 . 0 0 1 \mu \mathrm { I U / m L }$ .

# Limit of Detection:

Lumipulse G TSH-III Calibrator 2 Solution Stock was diluted with ultrafiltration charcoal adsorbed human serum to create eight low-level TSH serum pools. Samples were tested using two reagent lots over 15 days of testing $( \mathtt { n } = 6 0$ for each panel and lot combination). The limit of detection was determined to be $0 . 0 0 2 \mu \mathrm { I U / m L }$ .

# Limit of Quantitation:

The limit of quantitation was determined using eight low-level TSH serum pools. The limit of quantitation was defined as the value at which the between run CV is $20 \%$ , and determined to be $0 . 0 0 6 \mu \mathrm { I U / m L }$ .

The claimed measuring range is $0 . 0 2 \mathrm { ~ - ~ } 1 0 0 ~ \mu \mathrm { I U / m L }$ .

# e. Analytical specificity:

An interference study was conducted to evaluate the effect of endogenous interference substances using the Lumipulse G TSH-III on the LUMIPULSE G1200 system. Three native serum pools containing low $( 0 . 5 \mu \mathrm { I U / m L }$ ), medium (2-3 $\mu \mathrm { I U / m L } ,$ ), and high concentrations $6 6 { - } 7 2 \ \mu \mathrm { I U / m L }$ of TSH were tested by spiking with potential interferents or an equivalent volume of diluent. A significant difference was defined as greater than $10 \%$ different in the test and control serum pools.

No significant interferences were observed for the substances and concentrations listed below:

<table><tr><td rowspan=1 colspan=1>Interferent</td><td rowspan=1 colspan=1>Test Concentration</td></tr><tr><td rowspan=1 colspan=1>Conjugated Bilirubin</td><td rowspan=1 colspan=1>60 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Unconjugated Bilirubin</td><td rowspan=1 colspan=1>60 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Triglycerides (Intralipid)</td><td rowspan=1 colspan=1>3000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>500 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Albumin</td><td rowspan=1 colspan=1>12 g/dL</td></tr><tr><td rowspan=1 colspan=1>Immunoglobulin G</td><td rowspan=1 colspan=1>5 g/dL</td></tr><tr><td rowspan=1 colspan=1>Biotin</td><td rowspan=1 colspan=1>19.7 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Cholesterol</td><td rowspan=1 colspan=1>500 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Uric Acid</td><td rowspan=1 colspan=1>24 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid factor</td><td rowspan=1 colspan=1>1000 IU/mL</td></tr></table>

Exogenous interference:

The effect on quantitation of analyte in the presence of exogenous interferents was determined by comparing values obtained from samples spiked with drugs into three native human serum pools and tested with the Lumipulse G TSH-III on the LUMIPULSE G1200 system. The TSH analyte concentrations of the three serum pools were approximately $0 . 5 ~ { \mu \mathrm { I U / m L } }$ , $2 - 3 \mu \mathrm { I U / m L }$ , and $6 6 - 7 2 \ \mu \mathrm { I U / m L }$ . The sponsor defined non-significant interference as recovery within $\pm 1 0 \%$ .

No significant interferences were observed for the substances and concentrations listed below:

<table><tr><td rowspan=1 colspan=1>Interferent</td><td rowspan=1 colspan=1>Test Concentration</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>20 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Acetylsalicylic acid</td><td rowspan=1 colspan=1>65 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Amiodarone</td><td rowspan=1 colspan=1>0.6 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Atropine</td><td rowspan=1 colspan=1>20 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Ascorbic acid</td><td rowspan=1 colspan=1>6.5 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Caffeine</td><td rowspan=1 colspan=1>6 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Carbamazepine</td><td rowspan=1 colspan=1>1.2 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Dexamethasone</td><td rowspan=1 colspan=1>0.06 mg/dL</td></tr><tr><td rowspan=1 colspan=1>EDTA</td><td rowspan=1 colspan=1>0.1 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Ethanol</td><td rowspan=1 colspan=1>1%</td></tr><tr><td rowspan=1 colspan=1>Furosemide</td><td rowspan=1 colspan=1>6 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Gentisic acid</td><td rowspan=1 colspan=1>2 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Heparin</td><td rowspan=1 colspan=1>3000 U/L</td></tr><tr><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>50 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Prednisone</td><td rowspan=1 colspan=1>0.03 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Propranolol</td><td rowspan=1 colspan=1>0.23 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Theophylline</td><td rowspan=1 colspan=1>4 mg/dL</td></tr></table>

# Cross-reactivity:

A cross-reactivity study was conducted according to CLSI-EP7-A2 to evaluate the potential cross-reactivity of the assay. Potential cross-reactants were added into test pools, and an equivalent volume of diluent added to control pools. Cross-reactivity was calculated as follows:

$\%$ cross-reactivity $=$ [(mean concentration of spiked sample - mean concentration of unspiked sample) / spiked concentration] x 100

The following potentially cross-reacting compounds at the indicated concentrations, tested with TSH concentrations of approximately $0 . 5 \mu \mathrm { I U / m L }$ , $2 - 3 \ \mu \mathrm { I U / m L }$ , and 66 - $7 2 \ \mu \mathrm { I U / m L }$ , did not interfere with the performance of the device.

<table><tr><td rowspan=1 colspan=1>Potential Cross-Reactant</td><td rowspan=1 colspan=1>Concentration Tested</td></tr><tr><td rowspan=1 colspan=1>FSH</td><td rowspan=1 colspan=1>5000 mIU/mL</td></tr><tr><td rowspan=1 colspan=1>hCG</td><td rowspan=1 colspan=1>200000 mIU/mL</td></tr><tr><td rowspan=1 colspan=1>hGH</td><td rowspan=1 colspan=1>100 ng/mL</td></tr><tr><td rowspan=1 colspan=1>LH</td><td rowspan=1 colspan=1>1000 mIU/mL</td></tr></table>

# Human Anti-Mouse Antibodies:

To determine the susceptibility of Lumipulse G TSH-III to potential human antimouse antibody (HAMA) interference, three native serum pools with low, medium, and high TSH values were spiked with HAMA to a target of $1 2 6 8 ~ \mathrm { { n g / m L } }$ or an equivalent volume of diluent. Three replicates of each test and control serum pool were tested. No HAMA interference at a concentration up to $1 2 6 8 ~ \mathrm { { n g / m L } }$ was observed.

# High Dose Hook Effect:

To determine any hook effect, TSH was spiked into a low TSH serum pool to create target TSH concentrations of at least $5 0 0 0 ~ { \mu \mathrm { I U / m L } }$ . The signal levels of individual replicates of all samples with mean concentrations greater than $1 0 0 ~ \mathrm { \mu I U / m L }$ , up to $5 0 0 0 ~ { \mu \mathrm { I U / m L } }$ of TSH, were higher than signal responses at $1 0 0 ~ \mathrm { \mu I U / m L }$ . The sponsor concluded there was no high dose hook effect when samples up to $5 0 0 0 ~ \mu \mathrm { I U / m L }$ were assayed.

f. Assay cut-off:

Not applicable.

2. Comparison studies:

a. Method comparison with predicate device:

One-hundred and forty-one native serum specimens were tested using the candidate device on the LUMIPULSE G1200 System and the Abbott ARCHITECT TSH assay (predicate device). The results of weighted Deming regression are shown in the table below:

<table><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Sample Range(μIU/mL)</td><td rowspan=1 colspan=1>Slope (95% CI)</td><td rowspan=1 colspan=1>Intercept (95% CI)</td><td rowspan=1 colspan=1>r</td></tr><tr><td rowspan=1 colspan=1>141</td><td rowspan=1 colspan=1>0.030 to 89.930</td><td rowspan=1 colspan=1>0.9689(0.9259, 1.0119)</td><td rowspan=1 colspan=1>-0.0037(-0.0064, -0.0010)</td><td rowspan=1 colspan=1>0.9838</td></tr></table>

b. Matrix comparison:

Not applicable. Only serum samples are recommended for use with this assay.

3. Clinical studies:

a. Clinical Sensitivity: Not applicable.   
b. Clinical specificity: Not applicable.   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable.

4. Clinical cut-off: Not applicable.

5. Expected values/Reference range:

Remnant human serum samples from males and females over age 21 were obtained from commercial vendors. Samples were obtained from subjects that were self-reportedly healthy individuals with known TSH values that ranged between $0 . 3 \mathrm { ~ - ~ } 5 . 0 ~ \mu \mathrm { I U / m L }$ . Reference ranges were calculated using the central $9 5 \%$ interval (2.5th - 97.5th percentile) according to CLSI EP28-A3c. The reference interval is $0 . 3 8 9 \mathrm { ~ - } 3 . 7 6 4 ~ \mu \mathrm { { I U / m L } }$ .

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.